Talimogene laherparepvec (T-VEC)
Talimogene laherparepvec (T-VEC) is a first-in-class oncolytic viral immunotherapy and live, attenuated virus. More information about oncolytic viruses and virotherapy can be found here.
It is approved as intralesional treatment of unresectable cutaneous, subcutaneous, and/or nodal melanoma that cannot be surgically removed.
Provider Resource
